BR112015019587A2 - combinações compreendendo compostos maba e corticosteroides - Google Patents

combinações compreendendo compostos maba e corticosteroides

Info

Publication number
BR112015019587A2
BR112015019587A2 BR112015019587A BR112015019587A BR112015019587A2 BR 112015019587 A2 BR112015019587 A2 BR 112015019587A2 BR 112015019587 A BR112015019587 A BR 112015019587A BR 112015019587 A BR112015019587 A BR 112015019587A BR 112015019587 A2 BR112015019587 A2 BR 112015019587A2
Authority
BR
Brazil
Prior art keywords
corticosteroids
combinations
maba compounds
maba
compounds
Prior art date
Application number
BR112015019587A
Other languages
English (en)
Inventor
Gavalda Monedero Amadeu
Puig Duran Carlos
Calbet Murtro Marta
Aparici Virgili Monica
Miralpeix Guell Montserrat
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of BR112015019587A2 publication Critical patent/BR112015019587A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "combinações compreendendo compostos maba e corticosteroides". uma combinação compreendendo (a) corticosteroide e (b) um composto duplamente antagonista muscarínico - agonista ß2-adrenérgico, ou qualquer sal ou solvato farmaceuticamente aceitáveis dos mesmos.
BR112015019587A 2013-02-27 2014-02-27 combinações compreendendo compostos maba e corticosteroides BR112015019587A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13382060 2013-02-27
US201361804558P 2013-03-22 2013-03-22
EP13382290 2013-07-16
PCT/EP2014/053874 WO2014131852A1 (en) 2013-02-27 2014-02-27 Combinations comprising maba compounds and corticosteroids

Publications (1)

Publication Number Publication Date
BR112015019587A2 true BR112015019587A2 (pt) 2017-07-18

Family

ID=51427547

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019587A BR112015019587A2 (pt) 2013-02-27 2014-02-27 combinações compreendendo compostos maba e corticosteroides

Country Status (11)

Country Link
US (1) US20160015704A1 (pt)
EP (1) EP2988745A1 (pt)
JP (1) JP2016510012A (pt)
KR (1) KR20150120391A (pt)
CN (1) CN105007922A (pt)
AU (1) AU2014222646A1 (pt)
BR (1) BR112015019587A2 (pt)
CA (1) CA2901869A1 (pt)
TW (1) TW201440768A (pt)
UY (1) UY35354A (pt)
WO (1) WO2014131852A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
BR112015013628A2 (pt) 2012-12-18 2017-07-11 Almirall Sa derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
EP3484879B1 (en) * 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3603645A1 (en) * 2018-07-30 2020-02-05 Virbac Novel use of glucocorticoids for the treatment of epithelial microbial infections of a fluid containing organ with a natural exterior orifice in mammals
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0702413D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
CN102131505A (zh) * 2008-06-20 2011-07-20 阿斯利康(瑞典)有限公司 用于调节β2-肾上腺素受体活性的包含4-羟基-2-氧代-2，3-二氢-1，3-苯并噻唑-7-基化合物的药物组合物
DE102010016629B4 (de) * 2010-04-23 2015-11-19 FLUORON GmbH Gesellschaft für hochreine Biomaterialien Vorrichtung mit Vitrektomielinse
EP2386555A1 (en) * 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

Also Published As

Publication number Publication date
KR20150120391A (ko) 2015-10-27
EP2988745A1 (en) 2016-03-02
CA2901869A1 (en) 2014-09-04
CN105007922A (zh) 2015-10-28
TW201440768A (zh) 2014-11-01
US20160015704A1 (en) 2016-01-21
JP2016510012A (ja) 2016-04-04
UY35354A (es) 2014-09-30
WO2014131852A1 (en) 2014-09-04
AU2014222646A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
BR112015019587A2 (pt) combinações compreendendo compostos maba e corticosteroides
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
EA201690127A1 (ru) Состав на основе ингибиторов syk
PH12016500024A1 (en) Bromodomain inhibitor
MX2015010680A (es) Combinaciones que comprenden compuestos maba y corticosteroides.
NI201500135A (es) Composición farmacéutica de hidrocloruro de s-ketamina
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112014025041B8 (pt) Composição farmacêutica
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
UY35677A (es) Combinaciones que comprenden compuestos maba y corticosteroides
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
EP3995489A3 (en) Disulfide compounds for delivery of pharmaceutical agents
BR112015024075A2 (pt) compostos de piridinilpirazoloquinolina
BR112018008006A2 (pt) composto de piranodipiridina
TR201901687T4 (tr) Hepatik ensefalopati tedavisinde kullanıma yönelik steroid bileşik.
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]